Serveur d'exploration Tocilizumab - Checkpoint (Ncbi)

Index « Auteurs » - entrée « Arthur Kavanaugh »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Arthur Guerber < Arthur Kavanaugh < Arthur Lau  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 15.
Ident.Authors (with country if any)Title
000055 (2007) Arthur Kavanaugh [États-Unis]Interleukin-6 inhibition and clinical efficacy in rheumatoid arthritis treatment--data from randomized clinical trials.
000127 (2008) Stephanie Hennigan [États-Unis] ; Arthur KavanaughInterleukin-6 inhibitors in the treatment of rheumatoid arthritis.
000147 (2009) Maja Mircic [États-Unis] ; Arthur KavanaughThe clinical efficacy of tocilizumab in rheumatoid arthritis.
000373 (2011) Maja Mircic [États-Unis] ; Arthur KavanaughInhibition of IL6 in rheumatoid arthritis and juvenile idiopathic arthritis.
000463 (2012) Yusuf Yazici [États-Unis] ; Jeffrey R. Curtis ; Akgun Ince ; Herbert Baraf ; Raymond L. Malamet ; Lichen L. Teng ; Arthur KavanaughEfficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study.
000728 (????) Yusuf Yazici [États-Unis] ; Jeffrey R. Curtis ; Akgun Ince ; Herbert S B. Baraf ; Denise M. Lepley ; Jenny N. Devenport ; Arthur KavanaughEarly effects of tocilizumab in the treatment of moderate to severe active rheumatoid arthritis: a one-week sub-study of a randomised controlled trial (Rapid Onset and Systemic Efficacy [ROSE] Study).
000774 (2013) Cem Gabay [Suisse] ; Paul Emery ; Ronald Van Vollenhoven ; Ara Dikranian ; Rieke Alten ; Karel Pavelka ; Micki Klearman ; David Musselman ; Sunil Agarwal ; Jennifer Green ; Arthur KavanaughTocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial.
000776 (2013) Daniel E. Furst [États-Unis] ; Edward Clark Keystone ; Alexander K. So ; Jürgen Braun ; Ferry C. Breedveld ; Gerd R. Burmester ; Fabrizio De Benedetti ; Thomas Dörner ; Paul Emery ; Roy Fleischmann ; Allan Gibofsky ; J R Kalden ; Arthur Kavanaugh ; Bruce Kirkham ; Philip Mease ; A. Rubbert-Roth ; Joachim Sieper ; Nora G. Singer ; Josef S. Smolen ; Piet L C M. Van Riel ; Michael H. Weisman ; Kevin L. WinthropUpdated consensus statement on biological agents for the treatment of rheumatic diseases, 2012.
000808 (2013) Minyoung Her [Corée du Sud] ; Arthur KavanaughTreatment of spondyloarthropathy: the potential for agents other than TNF inhibitors.
000855 (2013) Cem Gabay [Suisse] ; Arthur Kavanaugh [États-Unis]Tocilizumab versus adalimumab for rheumatoid arthritis - Authors' reply.
000A49 (2014) Arthur Kavanaugh [États-Unis] ; Philip J. Mease [États-Unis] ; Juan J. Gomez-Reino [Espagne] ; Adewale O. Adebajo [Royaume-Uni] ; Jürgen Wollenhaupt [Allemagne] ; Dafna D. Gladman [Canada] ; Eric Lespessailles [France] ; Stephen Hall [Australie] ; Marla Hochfeld [États-Unis] ; Chiachi Hu [États-Unis] ; Douglas Hough [États-Unis] ; Randall M. Stevens [États-Unis] ; Georg Schett [Allemagne]Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
000B87 (2014) Glynn Dennis ; Cécile T J. Holweg ; Sarah K. Kummerfeld ; David F. Choy ; A Francesca Setiadi ; Jason A. Hackney ; Peter M. Haverty ; Houston Gilbert ; Wei Yu Lin ; Lauri Diehl ; S. Fischer ; An Song ; David Musselman ; Micki Klearman ; Cem Gabay ; Arthur Kavanaugh ; Judith Endres ; David A. Fox ; Flavius Martin ; Michael J. TownsendSynovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics.
001000 (2016) Cem Gabay [Suisse] ; Iain B. Mcinnes [Royaume-Uni] ; Arthur Kavanaugh [États-Unis] ; Katie Tuckwell [Royaume-Uni] ; Micki Klearman [États-Unis] ; Jennifer Pulley [Royaume-Uni] ; Naveed Sattar [Royaume-Uni]Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.
001754 (2017) Vibeke Strand [États-Unis] ; Margaret Michalska [États-Unis] ; Christine Birchwood [États-Unis] ; Jinglan Pei [États-Unis] ; Katie Tuckwell [États-Unis] ; Rebecca Finch [Royaume-Uni] ; Cem Gabay [Suisse] ; Arthur Kavanaugh [États-Unis] ; Graeme Jones [Australie]Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials.
002895 (2020) Michaela Koehm [Allemagne] ; Matthew J. Mcintosh [États-Unis] ; Michael W. Hofmann [Allemagne] ; Varghese Abraham [États-Unis] ; Cem Gabay [Suisse] ; Ernest H. Choy [Royaume-Uni] ; Arthur Kavanaugh [États-Unis] ; Harald Burkhardt [Allemagne] ; Frank Behrens [Allemagne]Individual therapeutic DAS28-dcrit responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studies.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Ncbi/Checkpoint
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/Author.i -k "Arthur Kavanaugh" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/Author.i  \
                -Sk "Arthur Kavanaugh" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Ncbi
   |étape=   Checkpoint
   |type=    indexItem
   |index=    Author.i
   |clé=    Arthur Kavanaugh
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021